Form 10-K Fulcrum Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Stifel on Fulcrum Therapeutics (FULC): 'we think overly nitpicking 19.3% is splitting hairs and misses the bigger picture'
February 24, 2026 10:23 AM ESTStifel analyst Dae Gon Ha reiterated a Buy rating and $25.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).
The analyst comments "The move this morning surprises us. While we think some thought total mean HbF may comfortably be >20% given the strength of the... More
